364 related articles for article (PubMed ID: 17070326)
1. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
Schaefer W
J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
[No Abstract] [Full Text] [Related]
2. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
Abrams P; Kaplan S; De Koning Gans HJ; Millard R
J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
[TBL] [Abstract][Full Text] [Related]
3. [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder].
Deng YJ; Ma G; Guo YF; Ge Z; Lu RG; Wang LX; Zhu HB; Chen CJ
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jan; 13(1):26-8. PubMed ID: 21251382
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
Roberts RG; Garely AD; Bavendam T
Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
[TBL] [Abstract][Full Text] [Related]
5. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.
Athanasopoulos AA; Perimenis PS
BJU Int; 2005 May; 95(7):1117-8. PubMed ID: 15839945
[No Abstract] [Full Text] [Related]
6. Tolterodine for treatment of overactive bladder.
Kanofsky JA; Nitti VW
Urol Clin North Am; 2006 Nov; 33(4):447-53, viii. PubMed ID: 17011380
[TBL] [Abstract][Full Text] [Related]
7. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
8. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Speakman MJ
Eur Urol; 2009 Sep; 56(3):542-3. PubMed ID: 19070420
[No Abstract] [Full Text] [Related]
9. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Dmochowski R
Eur Urol; 2009 Sep; 56(3):542. PubMed ID: 19070419
[No Abstract] [Full Text] [Related]
10. Fesoterodine for the treatment of overactive bladder.
Tzefos M; Dolder C; Olin JL
Ann Pharmacother; 2009 Dec; 43(12):1992-2000. PubMed ID: 19920160
[TBL] [Abstract][Full Text] [Related]
11. [More quality of life again with tolterodine].
Praxis (Bern 1994); 2006 Oct; 95(42):1636. PubMed ID: 17111848
[No Abstract] [Full Text] [Related]
12. Effectiveness of tolterodine in nonneurogenic voiding dysfunction.
Babu R
Indian Pediatr; 2006 Nov; 43(11):980-3. PubMed ID: 17151401
[TBL] [Abstract][Full Text] [Related]
13. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
[TBL] [Abstract][Full Text] [Related]
15. Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
Jonas U; Rackley RR
Eur Urol; 2006 Jan; 49(1):187-8; author reply 188-90. PubMed ID: 16310930
[No Abstract] [Full Text] [Related]
16. Tolterodine for the treatment of overactive bladder.
Salvatore S; Serati M; Bolis P
Expert Opin Pharmacother; 2008 May; 9(7):1249-55. PubMed ID: 18422481
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.
Dmochowski R; Abrams P; Marschall-Kehrel D; Wang JT; Guan Z
Eur Urol; 2007 Apr; 51(4):1054-64; discussion 1064. PubMed ID: 17097217
[TBL] [Abstract][Full Text] [Related]
18. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.
Hsiao SM; Chang TC; Wu WY; Chen CH; Yu HJ; Lin HH
J Obstet Gynaecol Res; 2011 Aug; 37(8):1084-91. PubMed ID: 21501328
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams.
Chung DE; Te AE; Staskin DR; Kaplan SA
Urology; 2010 May; 75(5):1144-8. PubMed ID: 20206978
[TBL] [Abstract][Full Text] [Related]
20. Tolterodine.
Nurs Times; 2006 Jun 6-12; 102(23):27. PubMed ID: 16784047
[No Abstract] [Full Text] [Related]
[Next] [New Search]